

Original Paper

Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

Kristina Klier¹, MA; Yash J Patel², MSc; Timo Schinköthe^{2,3}, Prof Dr; Nadia Harbeck⁴, Prof Dr Med; Annette Schmidt^{1,3}, Prof Dr

¹Institute of Sport Science, University of the Bundeswehr Munich, Neubiberg, Germany

²CANKADO GmbH, Ottobrunn, Germany

³Research Center for Smart Digital Health, University of the Bundeswehr Munich, Neubiberg, Germany

⁴Department of Gynecology and Obstetrics, Comprehensive Cancer Center of the Ludwig-Maximilians-University, Munich, Germany

Corresponding Author:

Annette Schmidt, Prof Dr

Institute of Sport Science

University of the Bundeswehr Munich

Werner-Heisenberg-Weg 39

Neubiberg, 85577

Germany

Phone: 49 89 6004 4412

Email: annette.schmidt@unibw.de

Abstract

Background: Numerous antineoplastic drugs such as chemotherapeutics have cardiotoxic side effects and can lead to long QT syndrome (LQTS). When diagnosed and treated in time, the potentially fatal outcomes of LQTS can be prevented. Therefore, regular electrocardiogram (ECG) assessments are critical to ensure patient safety. However, these assessments are associated with patient discomfort and require timely support of the attending oncologist by a cardiologist.

Objective: This study aimed to examine whether this approach can be made more efficient and comfortable by a smartphone app (QTc Tracker), supporting single-lead ECG records on site and transferring to a tele-cardiologist for an immediate diagnosis.

Methods: To evaluate the QTc Tracker, it was implemented in 54 cancer centers in Germany. In total, 266 corrected QT interval (QTc) diagnoses of 122 patients were recorded. Moreover, a questionnaire on routine ECG workflow, turnaround time, and satisfaction (1=best, 6=worst) was answered by the centers before and after the implementation of the QTc Tracker.

Results: Compared to the routine ECG workflow, the QTc Tracker enabled a substantial turnaround time reduction of 98% (mean 2.67, 95% CI 1.72-2.67 h) and even further time efficiency in combination with a cardiologic on-call service (mean 12.10, 95% CI 5.67-18.67 min). Additionally, nurses and patients reported higher satisfaction when using the QTc Tracker. In particular, patients' satisfaction sharply improved from 2.59 (95% CI 2.41-2.88) for the routine ECG workflow to 1.25 (95% CI 0.99-1.51) for the QTc Tracker workflow.

Conclusions: These results reveal a significant improvement regarding reduced turnaround time and increased user satisfaction. Best patient care might be guaranteed as the exposure of patients with an uncontrolled risk of QTc prolongations can be avoided by using the fast and easy QTc Tracker. In particular, as regular side-effect monitoring, the QTc Tracker app promises more convenience for patients and their physicians. Finally, future studies are needed to empirically test the usability and validity of such mobile ECG assessment methods.

Trial Registration: ClinicalTrials.gov NCT04055493; <https://classic.clinicaltrials.gov/ct2/show/NCT04055493>

(*JMIR Cardio* 2023;7:e48096) doi: [10.2196/48096](https://doi.org/10.2196/48096)

KEYWORDS

telemedicine; mobile health; mHealth; eHealth; tele-cardiology; cardiology; long QT syndrome; prolonged QT interval; electrocardiography; ECG; telehealth; app; application; oncology; cancer; diagnosis; diagnostic; heart; arrhythmia; cardiotoxic; side effects; adverse effects

Introduction

The potentially fatal long QT syndrome (LQTS) is one of the main cardiotoxic side effects of cancer drugs [1], including arsenic trioxide [2-6], selective cyclin-dependent kinase 4 and 6 inhibitors such as ribociclib [7-12], tyrosine kinase inhibitors such as vandetanib [13-18], or histone deacetylase inhibitors such as depsipeptide [19,20]. This syndrome is characterized by a prolongation of the corrected QT interval (QTc), which may induce life-threatening arrhythmias, including torsade de pointes (TdP), and can lead to sudden cardiac death [21]. The outcome of LQTS is not necessarily fatal when diagnosed and treated in time, as the medically induced prolongation of the QTc is reversible [22]. Multiple risk factors may contribute to the development of QTc prolongation. Increasing age as well as female sex, for example, are associated with a higher risk of prolonged QTc [23-27].

The normal average QTc for male individuals is approximately <430 ms, whereas the normal average QTc for female individuals is approximately <450 ms. A borderline QTc can be 431-450 ms for male individuals and 451-470 ms for female individuals, whereas a prolonged QTc is considered >450 ms for male individuals and >470 ms for female individuals [28]. An increased QTc of 10 ms contributes to a 5% to 7% exponential increased risk to develop the life-threatening arrhythmia TdP. Thus, a QTc of 540 ms exposes the patient to a 63% to 97% higher TdP risk than a QTc of 440 ms, but there is no QTc value at which TdP certainly occurs [29-31]. In the case of drug-induced LQTS with a QTc increased to >500 ms or a QTc prolongation of >60 ms above the baseline, treatment discontinuation or alternative therapies should be considered [1].

Regular QTc assessment is associated with additional effort for the attending physician and patient. In the context of oncologic treatments, QTc examination commonly requires the consultation of a cardiologist in addition to the attending oncologist, as many oncologists do not have the ability to record and diagnose electrocardiograms (ECGs) directly on-site. This situation forces the typically older patients with cancer to additionally visit a cardiologist, which in turn exposes them to more stress and endangers susceptible patients. Even if the oncologists can conduct an ECG themselves, this does not guarantee the correct QTc assessment, as only <25% of noncardiologists can correctly classify a QTc as prolonged or normal [32]. Additionally, a 12-lead ECG in general requires the patient to undress and lay down, which is especially uncomfortable for older patients. For example, antiembolism stockings can significantly impede the undressing process for an older patient, and putting the stockings back on after the measurement is often difficult for them [33]. Ultimately, all these mentioned challenges and disadvantages may contribute to the known underuse of ECG monitoring in routine patients

in oncology [34]. Therefore, the aim of this study was to examine whether this conventional procedure can be made more efficient and comfortable by a smartphone app (QTc Tracker; version 4.27.30; CANKADO GmbH), supporting single-lead ECG records on site and transferring to a tele-cardiologist for an immediate diagnosis.

Methods

Participants and Study Procedure

In total, 54 centers in Germany with 122 patients participated in the study, and 266 QTc diagnoses were recorded. A questionnaire on routine ECG workflow, turnaround time, and satisfaction was answered by the centers before and after the implementation of the QTc Tracker. The turnaround time of the QTc Tracker was accessed from the software itself. All participating patients were diagnosed with early breast cancer and were on ribociclib-based therapy. Since ribociclib can lead to drug-induced LQTS as an adverse drug reaction, patients were monitored by ECG via at least 3 points every 2 weeks at the start of therapy.

Ethical Considerations

The study was conducted according to the Declaration of Helsinki, and all participants provided informed written consent prior to the measurements. Ethical approval was provided by the West German Study Group (study ID: WSG-AM08). Participation was free and included no further risks. Participants were randomly assigned to numerical codes, so that data could be handled anonymously. The study is part of a registered trial (ClinicalTrials.gov; NCT04055493).

Questionnaire

The questionnaire used was developed from our own experiences and can be found in [Multimedia Appendix 1](#). It comprised 11 questions about the routine ECG workflow, turnaround time, and satisfaction. Answers were given from nurses' and patients' perspectives as free text and rated between 1 (best) and 6 (worst). All centers provided information about their routine ECG workflow and how they routinely receive the QTc diagnosis (paper based or digital).

KardiaMobile and Kardia App

The portable ECG device KardiaMobile (model AC-009; AliveCor Inc) was used to record the single-lead ECGs. The device has US Food and Drug Administration and European Union clearance and Conformité Européenne labeling as a medical device and can be used to calculate QT intervals and monitor drug-mediated QTc prolongation [35-37]. The device comprises 2 electrodes that are used to measure a single-lead ECG between both hands ([Figure 1](#)). The ECG recording is transmitted wirelessly to the respective Kardia App (version 5.7.4; AliveCor Inc).

Figure 1. Recording of an electrocardiogram (ECG) with the KardiaMobile Device connected to the Kardia App. The single-lead ECG is recorded by laying the fingers on the electrodes of the KardiaMobile ECG device. A smartphone is connected to the device and records the ECG.




QTc Tracker

During a routine check-up, the patient records a single-lead ECG on site at the cancer center with the KardiaMobile single-lead ECG device. A PDF file is created with the Kardia App and transferred to the QTc Tracker of the attending oncologist. The assignment of an ECG file to the corresponding patient’s record—either a new or an already existing patient—is guided using a unique patient ID. The QTc Tracker interface for oncologists shows each recorded ECG in an individual row.

Next to the patients’ ID is a colored circle, which represents the status of the QTc diagnosis request. If the diagnosis is still pending, the circle is gray. After diagnosis, the circle changes its color according to the Common Terminology Criteria for Adverse Events (CTCAE) grade of the QTc diagnosis. In the case of a normal QTc with a CTCAE grade of 0, the circle is green. If the QTc is pathologic, the color is either orange for a CTCAE grade of 1 or red for a CTCAE grade of 2 or higher (Figure 2).

Figure 2. Overview of the general QTc Tracker workflow. Immediate corrected QT interval diagnosis via smartphone app supporting single-lead ECG record on-site and transfer to tele-cardiologist.



When the oncologist requests the QTc diagnosis of the ECG file, both the request and the ECG data are transferred to a tele-cardiologist, who then receives a push notification. The QTc Tracker also comprises an interface for the tele-cardiologist

(Figure 2). This interface includes an overview of all pending QTc diagnosis requests sorted by the time of receipt. It is structured similar to the interface of the oncologist, with each row representing one request containing the unique patient’s

ID and the color-coded circle for the diagnosis status. A gray circle symbolizes a pending ECG diagnosis, whereas a green circle symbolizes the completed diagnosis. The tele-cardiologist is able to open specific requests and view the original ECG file recorded by the Kardia App for revision and diagnosis. Although the QT interval, QT SD, beats per minute, RR interval, QTc using the Fridericia formula (QTcF), and CTCAE grade are calculated automatically, the cardiologist is able to graphically adjust the QTc (Figure 2). The different elements of the ECG are extracted, so the ECG cycles can be identified and further analyzed. For each cardiac cycle, the QT interval is determined according to Martínez and colleagues [38] and corrected for the heart rate with the Fridericia formula (QTcF) as recommended by the European Society of Cardiology [1]. The correction formula according to Fridericia [39] is as follows:

$$QTcF = \frac{QT \text{ interval}}{\sqrt[3]{RR \text{ interval}}}$$

The RR interval is the interval between the R waves of 2 adjacent heart cycles. By determining the QRS onset and T offset (Figure 2), the QTcF is calculated automatically. An overlay plot of all cardiac cycles of an ECG is produced, displaying the mean cardiac cycle and the SD. The mean QTcF is also calculated and displayed.

According to *CTCAE version 5.0* [40,41], QTc prolongations are classified as follows: grade 1 is defined as an average QTc of 450–480 ms; grade 2 is defined as an average QTc of 481–500 ms; grade 3 is defined as an average QTc of >500 ms or a >60 ms change from baseline; and grade 4 is defined as the presence of TdP, polymorphic ventricular tachycardia, or serious

arrhythmia [40,41]. After the completion and submission of a diagnosis, the diagnostic report is generated as a PDF file and cannot be changed anymore. Additionally, a comment can be inserted by the tele-cardiologist into the diagnostic report. The details of a diagnostic report are saved in the electronic patient record and transmitted to the oncologist, who subsequently receives a push notification too. The QTc Tracker directly displays the CTCAE grade of a diagnosed ECG in the patient overview. For further details, the oncologist can view the complete diagnostic report. They also have the possibility to download the whole diagnostic report, print it, and add it to the local patient records.

Results

General Workflow

The fundamental principle of the telecardiology application QTc Tracker was the on-site ECG measurement at the cancer center and the direct transfer of the ECG data from the smartphone of the oncologist to the tele-cardiologist (Figure 2).

Routine ECG

The overall results of the questionnaire before the tracker's implementation are shown in Table 1. Not all centers answered all questions about the turnaround times of their routine ECG assessments. Information about the waiting time for an ECG appointment and the time span between ECG measurement and QTc diagnosis were obtained from 91% (49/54) and 87% (47/54) of the centers, respectively. The total turnaround time was obtained from 81% (45/54) of the centers, wherein both the waiting time for an ECG appointment and the time span between ECG measurement and QTc diagnosis were obtained.

Table 1. Overview of the different centers that participated in the study.

Group	Centers (N=54), n (%)	Diagnosis format, n/N (%)		Time to appointment, mean (95% CI)	Time to diagnosis after appointment, mean (95% CI)	Total turnaround time, mean (95% CI)
		Paper based	Digital			
Group 1 ^a	21 (39)	21/21 (100)	0/21 (0)	12.45 (2.90-22.00) d	3.79 (0.60-6.97) d	12.77 (2.83-22.70) d
Group 2 ^b	9 (17)	6/9 (67)	3/3 (33)	2.64 (0.13-5.14) d	1.14 (0.86-1.42) d	2.16 (0.23-4.08) d
Group 3 ^c	24 (44)	21/24 (88)	3/24 (12)	25.08 (15.50-34.65) min	51.98 (18.45-85.51) min	72.52 (36.84-108.20) min
Total	54 (100)	48/54 (89)	6/54 (11)	4.76 (1.12-8.40) d	1.64 (0.34-2.94) d	5.44 (1.43-9.45) d

^aGroup 1: centers without cardiologist.

^bGroup 2: centers with cardiologist who did not receive the corrected QT interval diagnosis on the same day.

^cGroup 3: centers with cardiologist who received the corrected QT interval diagnosis on the same day.

The 54 centers had a mean total turnaround time of 5.44 (95% CI 1.43-9.45) days, which was composed of a mean waiting time for an ECG appointment of 4.76 (95% CI 1.12-8.40) days and a mean time span between ECG measurement and QTc diagnosis of 1.64 (95% CI 0.34-2.94) days. Due to the high variation of the turnaround times, the centers were classified into 3 groups. Group 1 included centers without an in-house cardiologist (21/54, 39% of centers). Group 2 consisted of centers with their own cardiologist who did not receive the QTc diagnosis on the same day (9/54, 17%). Group 3 included centers

with their own cardiologist who received the QTc diagnosis on the same day (24/54, 44%).

QTc Tracker

The second part of the questionnaire about the workflow and turnaround time of using the QTc Tracker was answered by 12 centers. The total turnaround time of the QTc Tracker was retrieved from the system itself and comprised 266 QTc diagnoses, of which 223 (83.8%) were evaluable. Due to the sample size, the QTc Tracker results were not subdivided into groups but evaluated as a whole; therefore, group 4 represents

all centers using the QTc Tracker. The mean turnaround time of the QTc Tracker until the receipt of the diagnostic report by the oncologist was 2.67 (95% CI 1.72-2.67) hours. The time reduction from the mean turnaround time of all centers of 5.44 days to 2.67 hours equals to a reduction of 98%.

Further, a cardiologic on-call service was implemented as a trial to perform the QTc diagnosis. This workflow is constituted as group 5. Thereby, the mean turnaround time was further decreased to 12.10 (95% CI 5.67-18.67) minutes. In contrast to the routine ECG workflow, the mean total turnaround time was reduced by over 99%. The combination of the QTc Tracker with a cardiologic on-call service was tested for 28 QTc diagnoses.

Satisfaction

The majority of the centers (47/54, 87%) completed all questions about their satisfaction. Again, for the questions about the workflow and turnaround time, the second part of the questionnaire about satisfaction with the QTc Tracker workflow was answered by 12 centers.

The overall mean satisfaction grade of the nurses improved from 2.57 (95% CI 2.31-2.84) for the routine ECG workflow to 2.21 (95% CI 1.55-2.86) for the QTc Tracker workflow. The overall mean satisfaction grade of the patients improved from 2.65 (95% CI 2.41-2.88) for the routine ECG workflow to 1.25 (95% CI 0.99-1.51) for the QTc Tracker workflow. Common feedback from the study centers was relief from the patients as it was not necessary to visit a cardiologist in addition to the oncologist. Another positive feedback was the simplicity of the single-lead ECG measurement, especially because the patient does not need to undress for the procedure.

Discussion

Principal Findings

Since many medications ranging from antiarrhythmics to oncologic agents may prolong the QTc, it is necessary to search for a more comfortable and time-effective solution to monitor for QTc prolongation. Aside the conventional 12-lead ECG method, smartphone-dependent ECG devices were developed in recent years using a more convenient mode to measure ECGs without the need to undress. The versatility of mobile phones and the general accessibility to the internet enabled the possibility to use newly developed, smartphone-based heart rhythm monitors to assess the QTc directly on site with real-time tele-cardiologic QTc diagnosis, which in turn allows the practitioners to directly react in case of a prolongation.

Previous research confirmed the suitability of using single-lead ECGs recorded by the smartphone-based heart rhythm monitor

KardiaMobile to evaluate the QTc in various age and disease groups [35,37,42]. This new technology was shown to be very promising for outpatient QTc monitoring [36]. In general, the market of mobile and smartphone-based ECG devices is constantly expanding, with the perspective that such devices would be implemented into routine care in the next few years [37]. Apart from QTc prolongations as considered in this study, other heart rhythm disturbances can also be diagnosed including atrial fibrillation and atrial flutter [43].

To date, a change in the interaction between attending physicians and cardiologists for QTc diagnosis using single-lead ECGs was not an objective of previous research. The QTc Tracker is the first tele-cardiologic solution for QTc diagnosis using single-lead ECGs recorded by a KardiaMobile device. The field of telemedicine is a constantly evolving science that, according to the World Health Organization, comprises the provision of clinical support by connecting geographically separated users with modern information and communication technologies to improve health outcome [44]. Telemedicine was assessed as an important health care aspect that is under constant progress, with the perspective of it being implemented as a gold-standard technique in the future [45,46]. Currently, the majority of telemedicine systems address the topics of radiology and stroke care [46]. Especially regarding the recent COVID-19 pandemic, telemedicine is becoming more and more relevant [47,48], and therefore, more usable and efficient alternatives are needed.

However, some constraints are limiting our study. The first limitation is the dependency on technical support. In rural regions, internet support in general as well as technical support are not always given as needed for using the QTc Tracker. Another limitation is that we did not assess the accuracy of the measurements in this study but instead aimed for the usability of the assessment method. Therefore, further analysis of the accuracy of the QTc Tracker measurements is necessary. As the tool is promising for regular side-effect monitoring, it is currently integrated into several phase III-IV clinical trials in Germany. In the future, it is planned to use the QTc Tracker not only in combination with a central cardiology service but also to support the centers with their own cardiologists to conduct the diagnosis themselves.

Conclusions

The QTc Tracker provided a significant improvement for the cancer centers, enabling a highly reduced turnaround time and improved user satisfaction for QTc diagnoses. Finally, future studies should not only establish but also empirically test the usability and validity of such mobile ECG assessment methods.

Acknowledgments

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. We acknowledge open-access funding by the University of the Bundeswehr Munich.

Data Availability

The data sets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' Contributions

TS and AS contributed to the conceptualization of the manuscript. KK wrote the original draft. NH and YJP conducted the investigation. TS and AS contributed to writing—review and editing. All authors have read and agreed to the final version of the manuscript.

Conflicts of Interest

TS is the owner and managing director of CANKADO GmbH. The other authors declare that they have no conflicts of interest.

Multimedia Appendix 1

Questionnaire used in the study.

[\[DOCX File, 11 KB-Multimedia Appendix 1\]](#)

References

1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, ESC Scientific Document Group. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016 Sep 21;37(36):2768-2801 [FREE Full text] [doi: [10.1093/eurheartj/ehw211](https://doi.org/10.1093/eurheartj/ehw211)] [Medline: [27567406](https://pubmed.ncbi.nlm.nih.gov/27567406/)]
2. Roboz GJ, Ritchie EK, Carlin RF, Samuel M, Gale L, Provenzano-Gober JL, et al. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. *J Clin Oncol* 2014 Nov 20;32(33):3723-3728 [doi: [10.1200/JCO.2013.51.2913](https://doi.org/10.1200/JCO.2013.51.2913)] [Medline: [25245447](https://pubmed.ncbi.nlm.nih.gov/25245447/)]
3. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. *J Pharmacol Exp Ther* 2005 Jan;312(1):316-323 [doi: [10.1124/jpet.104.073692](https://doi.org/10.1124/jpet.104.073692)] [Medline: [15340016](https://pubmed.ncbi.nlm.nih.gov/15340016/)]
4. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. *J Clin Oncol* 2003 Oct 01;21(19):3609-3615 [doi: [10.1200/JCO.2003.10.009](https://doi.org/10.1200/JCO.2003.10.009)] [Medline: [14512391](https://pubmed.ncbi.nlm.nih.gov/14512391/)]
5. Hai JJ, Gill H, Tse H, Kumana CR, Kwong Y, Siu C. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. *Ann Hematol* 2015 Mar;94(3):501-503 [doi: [10.1007/s00277-014-2174-1](https://doi.org/10.1007/s00277-014-2174-1)] [Medline: [25079038](https://pubmed.ncbi.nlm.nih.gov/25079038/)]
6. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. *Br J Haematol* 2004 May;125(4):470-476 [FREE Full text] [doi: [10.1111/j.1365-2141.2004.04941.x](https://doi.org/10.1111/j.1365-2141.2004.04941.x)] [Medline: [15142117](https://pubmed.ncbi.nlm.nih.gov/15142117/)]
7. Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al. Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications. *BioDrugs* 2019 Dec;33(6):613-620 [doi: [10.1007/s40259-019-00382-1](https://doi.org/10.1007/s40259-019-00382-1)] [Medline: [31529317](https://pubmed.ncbi.nlm.nih.gov/31529317/)]
8. Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (lee011) in patients with advanced solid tumors and lymphomas. *Clin Cancer Res* 2016 Dec 01;22(23):5696-5705 [FREE Full text] [doi: [10.1158/1078-0432.CCR-16-1248](https://doi.org/10.1158/1078-0432.CCR-16-1248)] [Medline: [27542767](https://pubmed.ncbi.nlm.nih.gov/27542767/)]
9. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol* 2018 Jul 01;29(7):1541-1547 [FREE Full text] [doi: [10.1093/annonc/mdy155](https://doi.org/10.1093/annonc/mdy155)] [Medline: [29718092](https://pubmed.ncbi.nlm.nih.gov/29718092/)]
10. Tripathy D, Im S, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol* 2018 Jul;19(7):904-915 [doi: [10.1016/S1470-2045\(18\)30292-4](https://doi.org/10.1016/S1470-2045(18)30292-4)] [Medline: [29804902](https://pubmed.ncbi.nlm.nih.gov/29804902/)]
11. Burris HA, Chan A, Bardia A, Thaddeus Beck J, Sohn J, Neven P, et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. *Br J Cancer* 2021 Aug;125(5):679-686 [FREE Full text] [doi: [10.1038/s41416-021-01415-9](https://doi.org/10.1038/s41416-021-01415-9)] [Medline: [34158598](https://pubmed.ncbi.nlm.nih.gov/34158598/)]
12. Sanò MV, Martorana F, Lavenia G, Rossello R, Prestifilippo A, Sava S, et al. Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. *Expert Rev Anticancer Ther* 2022 Apr;22(4):343-351 [doi: [10.1080/14737140.2022.2052277](https://doi.org/10.1080/14737140.2022.2052277)] [Medline: [35303782](https://pubmed.ncbi.nlm.nih.gov/35303782/)]
13. Ashraf S, Shah N, Saad M, Jyala A, Vittorio TJ. Vandetanib-induced hyponatremia and torsades de pointes: a case report. *Cureus* 2022 Apr;14(4):e24556 [FREE Full text] [doi: [10.7759/cureus.24556](https://doi.org/10.7759/cureus.24556)] [Medline: [35651469](https://pubmed.ncbi.nlm.nih.gov/35651469/)]
14. Ton GN, Banaszynski ME, Kolesar JM. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. *Am J Health Syst Pharm* 2013 May 15;70(10):849-855 [doi: [10.2146/ajhp120253](https://doi.org/10.2146/ajhp120253)] [Medline: [23640345](https://pubmed.ncbi.nlm.nih.gov/23640345/)]
15. Krause DS, van Etten RA. Tyrosine kinases as targets for cancer therapy. *N Engl J Med* 2005 Jul 14;353(2):172-187 [FREE Full text] [doi: [10.1056/NEJMra044389](https://doi.org/10.1056/NEJMra044389)] [Medline: [16014887](https://pubmed.ncbi.nlm.nih.gov/16014887/)]

16. Holden SN, Eckhardt SG, Bassler R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. *Ann Oncol* 2005 Aug;16(8):1391-1397 [FREE Full text] [doi: [10.1093/annonc/mdi247](https://doi.org/10.1093/annonc/mdi247)] [Medline: [15905307](https://pubmed.ncbi.nlm.nih.gov/15905307/)]
17. Wells SAJ, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol* 2012 Jan 10;30(2):134-141 [FREE Full text] [doi: [10.1200/JCO.2011.35.5040](https://doi.org/10.1200/JCO.2011.35.5040)] [Medline: [22025146](https://pubmed.ncbi.nlm.nih.gov/22025146/)]
18. Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. *Clin Cancer Res* 2012 Jul 15;18(14):3722-3730 [doi: [10.1158/1078-0432.CCR-12-0411](https://doi.org/10.1158/1078-0432.CCR-12-0411)] [Medline: [22665903](https://pubmed.ncbi.nlm.nih.gov/22665903/)]
19. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. *Clin Cancer Res* 2006 Jun 15;12(12):3762-3773 [doi: [10.1158/1078-0432.CCR-05-2095](https://doi.org/10.1158/1078-0432.CCR-05-2095)] [Medline: [16778104](https://pubmed.ncbi.nlm.nih.gov/16778104/)]
20. Kim M, Thompson LA, Wenger SD, O'Bryant CL. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. *Ann Pharmacother* 2012 Oct;46(10):1340-1348 [doi: [10.1345/aph.1R036](https://doi.org/10.1345/aph.1R036)] [Medline: [22968522](https://pubmed.ncbi.nlm.nih.gov/22968522/)]
21. Arunachalam K, Lakshmanan S, Maan A, Kumar N, Dominic P. Impact of drug induced long QT syndrome: a systematic review. *J Clin Med Res* 2018 May;10(5):384-390 [FREE Full text] [doi: [10.14740/jocmr3338w](https://doi.org/10.14740/jocmr3338w)] [Medline: [29581800](https://pubmed.ncbi.nlm.nih.gov/29581800/)]
22. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. *ScientificWorldJournal* 2012 Apr 19;2012:212178 [FREE Full text] [doi: [10.1100/2012/212178](https://doi.org/10.1100/2012/212178)] [Medline: [22593664](https://pubmed.ncbi.nlm.nih.gov/22593664/)]
23. Fukui S, Katoh H, Tsuzuki N, Ishihara S, Otani N, Ooigawa H, et al. Multivariate analysis of risk factors for QT prolongation following subarachnoid hemorrhage. *Crit Care* 2003 Jun;7(3):R7-R12 [FREE Full text] [doi: [10.1186/cc2160](https://doi.org/10.1186/cc2160)] [Medline: [12793884](https://pubmed.ncbi.nlm.nih.gov/12793884/)]
24. Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson JL, et al. Long QT syndrome in adults. *J Am Coll Cardiol* 2007 Jan 23;49(3):329-337 [FREE Full text] [doi: [10.1016/j.jacc.2006.08.057](https://doi.org/10.1016/j.jacc.2006.08.057)] [Medline: [17239714](https://pubmed.ncbi.nlm.nih.gov/17239714/)]
25. Jardin CGM, Putney D, Michaud S. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents. *Ann Pharmacother* 2014 Mar;48(2):196-202 [doi: [10.1177/1060028013512614](https://doi.org/10.1177/1060028013512614)] [Medline: [24301687](https://pubmed.ncbi.nlm.nih.gov/24301687/)]
26. Rabkin SW, Cheng XJ, Thompson DJ. Detailed analysis of the impact of age on the QT interval. *J Geriatr Cardiol* 2016 Sep;13(9):740-748 [FREE Full text] [doi: [10.11909/j.issn.1671-5411.2016.09.013](https://doi.org/10.11909/j.issn.1671-5411.2016.09.013)] [Medline: [27899938](https://pubmed.ncbi.nlm.nih.gov/27899938/)]
27. Johannesen L, Garnett C, Luo M, Targum S, Sørensen JS, Mehrotra N. Quantitative understanding of QTc prolongation and gender as risk factors for torsade de pointes. *Clin Pharmacol Ther* 2018 Mar;103(2):304-309 [doi: [10.1002/cpt.783](https://doi.org/10.1002/cpt.783)] [Medline: [29219167](https://pubmed.ncbi.nlm.nih.gov/29219167/)]
28. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Food and Drug Administration. 2005 Oct. URL: <https://www.fda.gov/files/drugs/published/E14-Clinical-Evaluation-of-QT-QTc-Interval-Prolongation-and-Proarrhythmic-Potential-for-Non-Antiarrhythmic-Drugs.pdf> [accessed 2023-08-30]
29. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Council on Cardiovascular Nursing, American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2010 Mar 02;55(9):934-947 [FREE Full text] [doi: [10.1016/j.jacc.2010.01.001](https://doi.org/10.1016/j.jacc.2010.01.001)] [Medline: [20185054](https://pubmed.ncbi.nlm.nih.gov/20185054/)]
30. Straus SMJM, Kors JA, de Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol* 2006 Jan 17;47(2):362-367 [FREE Full text] [doi: [10.1016/j.jacc.2005.08.067](https://doi.org/10.1016/j.jacc.2005.08.067)] [Medline: [16412861](https://pubmed.ncbi.nlm.nih.gov/16412861/)]
31. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. *Circulation* 1991 Jun;83(6):1888-1894 [doi: [10.1161/01.cir.83.6.1888](https://doi.org/10.1161/01.cir.83.6.1888)] [Medline: [2040041](https://pubmed.ncbi.nlm.nih.gov/2040041/)]
32. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. *Heart Rhythm* 2005 Jun;2(6):569-574 [doi: [10.1016/j.hrthm.2005.02.011](https://doi.org/10.1016/j.hrthm.2005.02.011)] [Medline: [15922261](https://pubmed.ncbi.nlm.nih.gov/15922261/)]
33. Thomas N, Bennett N. Introducing a device to assist in the application of anti-embolism stockings. *Br J Nurs* 2017 May 11;26(9):510-513 [doi: [10.12968/bjon.2017.26.9.510](https://doi.org/10.12968/bjon.2017.26.9.510)] [Medline: [28493771](https://pubmed.ncbi.nlm.nih.gov/28493771/)]
34. Pezo RC, Yan AT, Earle C, Chan KK. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. *Heart* 2019 Nov;105(21):1649-1655 [doi: [10.1136/heartjnl-2018-314674](https://doi.org/10.1136/heartjnl-2018-314674)] [Medline: [31129611](https://pubmed.ncbi.nlm.nih.gov/31129611/)]
35. Chung EH, Guise KD. QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation. *J Electrocardiol* 2015 Jan;48(1):8-9 [doi: [10.1016/j.jelectrocard.2014.10.005](https://doi.org/10.1016/j.jelectrocard.2014.10.005)] [Medline: [25453194](https://pubmed.ncbi.nlm.nih.gov/25453194/)]

36. Garabelli P, Stavrakis S, Albert M, Koomson E, Parwani P, Chohan J, et al. Comparison of QT interval readings in normal sinus rhythm between a smartphone heart monitor and a 12-lead ECG for healthy volunteers and inpatients receiving sotalol or dofetilide. *J Cardiovasc Electrophysiol* 2016 Jul;27(7):827-832 [doi: [10.1111/jce.12976](https://doi.org/10.1111/jce.12976)] [Medline: [27027653](https://pubmed.ncbi.nlm.nih.gov/27027653/)]
37. Koltowski L, Balsam P, Glowczynska R, Rokicki JK, Peller M, Maksym J, et al. Kardia Mobile applicability in clinical practice: A comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center. *Cardiol J* 2021;28(4):543-548 [FREE Full text] [doi: [10.5603/CJ.a2019.0001](https://doi.org/10.5603/CJ.a2019.0001)] [Medline: [30644079](https://pubmed.ncbi.nlm.nih.gov/30644079/)]
38. Martínez JP, Almeida R, Olmos S, Rocha AP, Laguna P. A wavelet-based ECG delineator: evaluation on standard databases. *IEEE Trans Biomed Eng* 2004 Apr;51(4):570-581 [doi: [10.1109/TBME.2003.821031](https://doi.org/10.1109/TBME.2003.821031)] [Medline: [15072211](https://pubmed.ncbi.nlm.nih.gov/15072211/)]
39. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Article in German. *Acta Med Scand* 1921;54:17-50 [doi: [10.1111/j.0954-6820.1921.tb15167.x](https://doi.org/10.1111/j.0954-6820.1921.tb15167.x)]
40. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute. 2017 Nov 27. URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf [accessed 2023-08-30]
41. Basch E, Reeve BB, Mitchell SA, Clouser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst* 2014 Sep;106(9):dju244 [FREE Full text] [doi: [10.1093/jnci/dju244](https://doi.org/10.1093/jnci/dju244)] [Medline: [25265940](https://pubmed.ncbi.nlm.nih.gov/25265940/)]
42. Karacan M, Celik N, Gul EE, Akdeniz C, Tuzcu V. Validation of a smartphone-based electrocardiography in the screening of QT intervals in children. *North Clin Istanbul* 2019 Feb 12;6(1):48-52 [FREE Full text] [doi: [10.14744/nci.2018.44452](https://doi.org/10.14744/nci.2018.44452)] [Medline: [31180383](https://pubmed.ncbi.nlm.nih.gov/31180383/)]
43. Himmelreich JCL, Karregat EPM, Lucassen WAM, van Weert HCPM, de Groot JR, Handoko ML, et al. Diagnostic accuracy of a smartphone-operated, single-lead electrocardiography device for detection of rhythm and conduction abnormalities in primary care. *Ann Fam Med* 2019 Sep;17(5):403-411 [FREE Full text] [doi: [10.1370/afm.2438](https://doi.org/10.1370/afm.2438)] [Medline: [31501201](https://pubmed.ncbi.nlm.nih.gov/31501201/)]
44. Ryu S. Telemedicine: opportunities and developments in member states: report on the Second Global Survey on eHealth 2009 (Global Observatory for eHealth Series, Volume 2). *Healthc Inform Res* 2012 Jun 30;18(2):153-155 [doi: [10.4258/hir.2012.18.2.153](https://doi.org/10.4258/hir.2012.18.2.153)]
45. Zhang XY, Zhang P. Telemedicine in clinical setting. *Exp Ther Med* 2016 Oct;12(4):2405-2407 [FREE Full text] [doi: [10.3892/etm.2016.3656](https://doi.org/10.3892/etm.2016.3656)] [Medline: [27703503](https://pubmed.ncbi.nlm.nih.gov/27703503/)]
46. Mechanic OJ, Persaud Y, Kimball AB. Telehealth systems. In: *StatPearls*. Treasure Island, FL: StatPearls Publishing; Sep 12, 2022.
47. Sevilla-Sánchez D, Tuset-Creus M. Pharmaceutical care in hospitalized patients. (management of the COVID-19 pandemic crisis. a new challenge for pharmacy services). *Farm Hosp* 2020 Jun 12;44(7):28-31 [doi: [10.7399/fh.11513](https://doi.org/10.7399/fh.11513)] [Medline: [32533666](https://pubmed.ncbi.nlm.nih.gov/32533666/)]
48. Strik M, Caillol T, Ramirez FD, Abu-Alrub S, Marchand H, Welte N, et al. Validating QT-interval measurement using the Apple Watch ECG to enable remote monitoring during the COVID-19 pandemic. *Circulation* 2020 Jul 28;142(4):416-418 [FREE Full text] [doi: [10.1161/CIRCULATIONAHA.120.048253](https://doi.org/10.1161/CIRCULATIONAHA.120.048253)] [Medline: [32478565](https://pubmed.ncbi.nlm.nih.gov/32478565/)]

Abbreviations

CTCAE: Common Terminology Criteria for Adverse Events

ECG: electrocardiogram

LQTS: long QT syndrome

QTc: corrected QT interval

QTcF: QT interval corrected for heart rate using the Fridericia formula

TdP: torsade de pointes

Edited by A Mavragani; submitted 11.04.23; peer-reviewed by C Jacob, A Baranchuk; comments to author 30.05.23; revised version received 20.06.23; accepted 21.06.23; published 11.09.23

Please cite as:

Klier K, Patel YJ, Schinköthe T, Harbeck N, Schmidt A

Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

JMIR Cardio 2023;7:e48096

URL: <https://cardio.jmir.org/2023/1/e48096>

doi: [10.2196/48096](https://doi.org/10.2196/48096)

PMID: [37695655](https://pubmed.ncbi.nlm.nih.gov/37695655/)

©Kristina Klier, Yash J Patel, Timo Schinköthe, Nadia Harbeck, Annette Schmidt. Originally published in JMIR Cardio (<https://cardio.jmir.org>), 11.09.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on <https://cardio.jmir.org>, as well as this copyright and license information must be included.